COVID-19与免疫血栓形成:新认识与临床管理
该综述总结了COVID-19相关凝血病与免疫血栓形成的病理生理机制及临床管理进展。早期武汉研究提示凝血病与死亡率显著相关,免疫血栓形成在重症COVID-19中起关键作用,血浆和心肺组织可检测到细胞外组蛋白和中性粒细胞胞外诱捕网。靶向免疫血栓形成成分、抗凝治疗及免疫调节治疗(如皮质类固醇和IL-6受体拮抗剂)是重要治疗方向。
要点
- 免疫血栓形成在重症COVID-19病理生理中起关键作用。
- 重症患者血浆和心肺组织可检测到细胞外组蛋白和中性粒细胞胞外诱捕网。
- 抗凝治疗需权衡不同疾病严重程度下的剂量与出血风险。
核心结论
- 免疫血栓形成在重症COVID-19病理生理中起关键作用。
- 靶向免疫血栓形成成分成为COVID-19治疗的重要方向。
研究设计与样本
- 综述,总结全球关于COVID-19相关凝血病和免疫血栓形成的研究证据。
主要发现
- 早期武汉研究提示COVID-19相关凝血病与死亡率显著相关。
- 重症患者血浆和心肺组织可检测到细胞外组蛋白和中性粒细胞胞外诱捕网。
- 近期研究报告了住院COVID-19患者中间剂量和治疗剂量抗凝的结局,包括最佳剂量和出血风险。
- 皮质类固醇和IL-6受体拮抗剂等免疫调节治疗已显示可显著降低COVID-19患者死亡率。
临床怎么用
- 临床需关注COVID-19患者的凝血功能异常和免疫血栓形成。
- 根据疾病严重程度选择抗凝剂量并监测出血风险。
- 免疫调节治疗(皮质类固醇、IL-6受体拮抗剂)可用于降低死亡率。
局限性
- 需更多研究理解COVID-19凝血病和免疫血栓形成的驱动因素及上游机制。
- 需开发针对急性期和长期症状负担的SARS-CoV-2感染靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has been the most significant health crisis in recent global history. Early studies from Wuhan highlighted COVID-19-associated coagulopathy and a significant association with mortality was soon recognised. As research continues across the world, more evidence is emerging of the cross-talk between the innate immune system, coagulation activation and inflammation. Immunothrombosis has been demonstrated to play a key role in the pathophysiology of severe COVID-19, with extracellular histones and neutrophil extracellular traps detected in the plasma and cardiopulmonary tissues of critically ill patients. Targeting the components of immunothrombosis is becoming an important factor in the treatment of patients with COVID-19 infection. Recent studies report outcomes of intermediate and therapeutic anticoagulation in hospitalised patients with varying severities of COVID-19 disease, including optimal dosing and associated bleeding risks. Immunomodulatory therapies, including corticosteroids and IL-6 receptor antagonists, have been demonstrated to significantly reduce mortality in COVID-19 patients. As the pandemic continues, more studies are required to understand the driving factors and upstream mechanisms for coagulopathy and immunothrombosis in COVID-19, and thus potentially develop more targeted therapies for SARS-CoV-2 infection, both in the acute phase and in those who develop longer-term symptom burden.
引用
- Shaw RJ, Bradbury C, Abrams ST, et al. COVID-19 and immunothrombosis: emerging understanding and clinical management. Br J Haematol. 2021. PMID: 34114204. doi:10.1111/bjh.17664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。